Repotrectinib Patent Expiration
Repotrectinib is Used for treating locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adult patients. It was first introduced by Bristol Myers Squibb Co
Repotrectinib Patents
Given below is the list of patents protecting Repotrectinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Augtyro | US11452725 | Chiral diaryl macrocycles and uses thereof | Jul 24, 2036 | Bristol |
| Augtyro | US10294242 | Diaryl macrocycle polymorph | Jul 05, 2036 | Bristol |
| Augtyro | US9714258 | Diaryl macrocycles as modulators of protein kinases | Jan 23, 2035 | Bristol |
Repotrectinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List